G6PD inhibitors are designed to disrupt the enzyme's activity, thereby impairing the PPP. This inhibition can lead to reduced availability of ribose-5-phosphate and NADPH, thereby limiting nucleotide synthesis and increasing oxidative stress in cancer cells. As a result, these inhibitors can potentially halt tumor growth and induce apoptosis by exploiting the cancer cells' dependency on G6PD for survival and proliferation.
